Research Paper Volume 12, Issue 3 pp 2992—3009

EGF released from human placental mesenchymal stem cells improves premature ovarian insufficiency via NRF2/HO-1 activation

Figure 6. EGF derived from hPMSCs suppressed ROS by upregulating the NRF2/HO-1 pathway in vitro. (A) qPCR analysis of the mRNA expression levels of PI3K, AKT and PTEN in POI hGCs after hPMSC or EGF (with 10 ng/ml, 20 ng/ml, and 40 ng/ml) treatment. (B) Western blot analysis of the protein levels of PI3K, AKT and PTEN in POI hGCs after hPMSC and EGF (with 10 ng/ml, 20 ng/ml, and 40 ng/ml) treatment. (C) qPCR analysis of the mRNA levels of NRF2 and HO-1 in POI hGCs after hPMSC or EGF (with 10 ng/ml, 20 ng/ml, and 40 ng/ml) treatment. (D) Western blot analysis of the protein levels of NRF2 and HO-1 in POI hGCs after hPMSC or EGF (with 10 ng/ml, 20 ng/ml, and 40 ng/ml) treatment. (E) Western blot analysis of the protein levels of NRF2, HO-1, CASPASE 3 and CASPASE 9 in H2O2-treated hGCs after EGF (with different concentrations) coculture. All experiments were carried out three times. The error bars indicate the SD; *** p < 0.001 (compared with the POI group). POI = premature ovarian insufficiency. The qPCR primer sequences used are listed in Supplementary Table 1.